CYP2E1 and metabolic dysfunction-associated steatotic liver disease: However, the interplay between CYP2E1, the microbiome, and NAFLD is still poorly understood, with further studies required to elucidate the effects of the gut microbiota on intestinal and hepatic CYP2E1 and eventually the pathogenesis of NAFLD and NASH.